AUTHOR=Engels Benedikt , Gevaert Thierry , Sermeus Alexandra , De Ridder Mark 

TITLE=Current Status of Intensified Neo-Adjuvant Systemic Therapy in Locally Advanced Rectal Cancer

JOURNAL=Frontiers in Oncology

VOLUME=Volume 2 - 2012

YEAR=2012

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2012.00047

DOI=10.3389/fonc.2012.00047

ISSN=2234-943X

ABSTRACT=The addition of 5-fluorouracil (5-FU) or its prodrug capecitabine to radiotherapy (RT) is a standard approach in the neo-adjuvant treatment of patients with rectal tumors extending beyond the muscularis propria (stage II) and/or with clinical evidence of regional lymph node metastases (stage III). According to European randomized trials, the combined treatment modality resulted in favorable local control (LC) rates as compared with radiotherapy (RT) alone, but no improvement was found regarding the occurrence of distant metastases or overall survival (OS). In an effort to further enhance the response rates and to decrease the high incidence of distant metastases in locally advanced rectal cancer patients, the addition of other chemotherapeutical drugs and biologic agents as radiation sensitizers to neo-adjuvant 5-FU based chemoradiotherapy (CRT) has been recently investigated. The role of those agents is however questionable as first results from phase III data do not show improvement on pathologic complete remission (pCR) and circumferential resection margin (CRM) negative resection rates as compared to 5-FU based CRT, nevertheless an increased toxicity.